{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:55:31Z","timestamp":1793933731790,"version":"4.8.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"Supplement_B","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiac amyloidosis (CA) is an infiltrative disease caused by progressive deposition of amyloid fibres in the heart. The most common forms include immunoglobulin light-chain and transthyretin amyloidosis. Current therapies for CA either stabilize or block the production of amyloidogenic precursors, preventing further amyloid deposition. This approach, while reducing cell damage and disease progression, does not target pre-existing amyloid deposits. Conversely, amyloid removal might stimulate functional recovery of the affected organ, thus improving quality of life and survival. A therapeutic strategy based on monoclonal antibodies capable of selectively binding amyloid deposits and inducing their removal has recently been tested in various clinical trial, with promising results, and could represent a key treatment for CA in the near future.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad079","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T18:03:16Z","timestamp":1682100196000},"page":"B79-B84","source":"Crossref","is-referenced-by-count":30,"title":["Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis"],"prefix":"10.1093","volume":"25","author":[{"given":"Michele","family":"Emdin","sequence":"first","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna , Pisa"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , Pisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Morfino","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna , Pisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Crosta","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna , Pisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna , Pisa"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , Pisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna , Pisa"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , Pisa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Health Sciences, Scuola Superiore Sant\u2019Anna , Pisa"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , Pisa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2023042117455315400_suad079-B1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.05.018","article-title":"Therapies for cardiac light chain amyloidosis: an update","volume":"271","author":"Aimo","year":"2018","journal-title":"Int J Cardiol"},{"key":"2023042117455315400_suad079-B2","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"2023042117455315400_suad079-B3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2023042117455315400_suad079-B4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","article-title":"Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis","volume":"36","author":"Nuvolone","year":"2022","journal-title":"BioDrugs"},{"key":"2023042117455315400_suad079-B5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2023042117455315400_suad079-B6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2023042117455315400_suad079-B7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"2023042117455315400_suad079-B8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11864-021-00922-4","article-title":"Immunotherapy in AL amyloidosis","volume":"23","author":"Zhang","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2023042117455315400_suad079-B9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-143180","article-title":"A phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated AL amyloidosis (SWOG S1702; NCT#03499808)","volume":"136","author":"Parker","year":"2020","journal-title":"Blood"},{"key":"2023042117455315400_suad079-B10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjh.16436","article-title":"Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits","volume":"189","author":"Popkova","year":"2020","journal-title":"Br J Haematol"},{"key":"2023042117455315400_suad079-B11","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"2023042117455315400_suad079-B12","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"2023042117455315400_suad079-B13","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","article-title":"A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model","volume":"41","author":"George","year":"2020","journal-title":"Eur Heart J"},{"key":"2023042117455315400_suad079-B14","first-page":"232","article-title":"Amiloidosi cardiaca. Come si diagnostica, come si cura\u2014di Michele Emdin, Giuseppe Vergaro, Claudio Passino","volume":"23","author":"Rapezzi","year":"2022","journal-title":"G Ital Cardiol (Rome)"},{"key":"2023042117455315400_suad079-B15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"2023042117455315400_suad079-B16","doi-asserted-by":"crossref","first-page":"eaam3128","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B79\/50061145\/suad079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B79\/50061145\/suad079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T18:03:25Z","timestamp":1682100205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_B\/B79\/7135793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":16,"journal-issue":{"issue":"Supplement_B","published-online":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad079","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,4,1]]}}}